The antidepressant drug, sertraline, hinders bone healing and osseointegration in rats’ tibiae

25Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Aim: Selective serotonin reuptake inhibitors (SSRIs) are one of the most common antidepressant drugs. SSRI use is associated with increased risk of bone fracture and titanium implant failure. The aim of this in vivo study was to investigate the effect of SSRIs on osseointegration and bone healing. Materials and Methods: On a total of 24 Sprague-Dawley rats, a custom-made titanium implant was placed in the left tibia, while a unicortical defect was created in the right tibia. Rats were assigned randomly into two groups and received a daily dose of either sertraline (5 mg/kg) or saline. After two weeks, they were euthanized and bone healing and osseointegration were assessed by micro-CT and histology. Results: Bone formation in bone defects was significantly lower (p < 0.05) in sertraline-treated rats (BV/TV = 20.67 ± 11.98%) compared to the controls (BV/TV = 37.87 ± 9.56%). Furthermore, the percentage of osseointegration was significantly lower (p < 0.05) in sertraline-treated rats (34.40 ± 7.17%) compared to the controls (54.37 ± 8.58%). Conclusion: Sertraline hinders bone healing and implant osseointegration.

Cite

CITATION STYLE

APA

Abu Nada, L., Al Subaie, A., Mansour, A., Wu, X., Abdallah, M. N., Al-Waeli, H., … Tamimi, F. (2018). The antidepressant drug, sertraline, hinders bone healing and osseointegration in rats’ tibiae. Journal of Clinical Periodontology, 45(12), 1485–1497. https://doi.org/10.1111/jcpe.13015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free